148 related articles for article (PubMed ID: 10609798)
1. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
Fonseca R; Hoyer JD; Aguayo P; Jalal SM; Ahmann GJ; Rajkumar SV; Witzig TE; Lacy MQ; Dispenzieri A; Gertz MA; Kyle RA; Greipp PR
Leuk Lymphoma; 1999 Nov; 35(5-6):599-605. PubMed ID: 10609798
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases.
Fonseca R; Witzig TE; Gertz MA; Kyle RA; Hoyer JD; Jalal SM; Greipp PR
Br J Haematol; 1998 May; 101(2):296-301. PubMed ID: 9609525
[TBL] [Abstract][Full Text] [Related]
3. MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes.
Yamamoto K; Yakushijin K; Ito M; Goto H; Higashime A; Kajimoto K; Hayashi Y; Matsuoka H; Minami H
Cancer Genet; 2020 Apr; 242():35-40. PubMed ID: 32035866
[TBL] [Abstract][Full Text] [Related]
4. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
Sasaki K; Lu G; Saliba RM; Bashir Q; Hosing C; Popat U; Shah N; Parmar S; Dinh Y; Ahmed S; Shpall EJ; Kebriaei P; Shah JJ; Orlowski RZ; Champlin R; Qazilbash MH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1227-32. PubMed ID: 23733001
[TBL] [Abstract][Full Text] [Related]
5. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.
Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ
Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884
[TBL] [Abstract][Full Text] [Related]
6. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Fonseca R; Blood EA; Oken MM; Kyle RA; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Hoyer JD; Harrington D; Kay NE; Van Ness B; Greipp PR
Blood; 2002 May; 99(10):3735-41. PubMed ID: 11986230
[TBL] [Abstract][Full Text] [Related]
7. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
8. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32).
Kobayashi H; Saito H; Kitano K; Kiyosawa K; Gaun S; Aoki K; Narita A; Watanabe M; Uchimaru K; Motokura T
Acta Haematol; 1995; 94(4):199-203. PubMed ID: 8610478
[TBL] [Abstract][Full Text] [Related]
10. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.
Vaandrager JW; Kluin P; Schuuring E
Blood; 1997 Jan; 89(1):349-50. PubMed ID: 8978314
[No Abstract] [Full Text] [Related]
11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
12. PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
Sato K; Sakai H; Kato M; Nishio Y; Tsuruoka Y; Uemura Y; Yokoi S; Saito T; Matsunawa M; Suzuki Y; Isobe Y; Inoue Y; Takahashi M; Miura I
Int J Hematol; 2015 Jun; 101(6):608-11. PubMed ID: 25633778
[TBL] [Abstract][Full Text] [Related]
13. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
[TBL] [Abstract][Full Text] [Related]
14. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
[TBL] [Abstract][Full Text] [Related]
15. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Gran C; Uttervall K; Borg Bruchfeld J; Wallblom A; Alici E; Gahrton G; Nahi H
Eur J Haematol; 2019 Dec; 103(6):588-596. PubMed ID: 31487754
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant.
Laï JL; Michaux L; Dastugue N; Vasseur F; Daudignon A; Facon T; Bauters F; Zandecki M
Cancer Genet Cytogenet; 1998 Jul; 104(2):133-8. PubMed ID: 9666807
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5.
Yokoi S; Sakai H; Uchida A; Uemura Y; Sato K; Tsuruoka Y; Nishio Y; Matsunawa M; Suzuki Y; Isobe Y; Kato M; Inoue Y; Hoshikawa M; Miura I
J Clin Exp Hematop; 2015; 55(3):137-43. PubMed ID: 26763361
[TBL] [Abstract][Full Text] [Related]
18. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.
Yufu Y; Goto T; Choi I; Uike N; Kozuru M; Ohshima K; Taniguchi T; Motokura T; Yatabe Y; Nakamura S
Cancer; 1999 Apr; 85(8):1750-7. PubMed ID: 10223569
[TBL] [Abstract][Full Text] [Related]
19. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
20. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
